Literature DB >> 24583559

[Preliminary experiences with low-dose computed tomography for lung cancer screening in Hungary].

Mariann Moizs1, Gábor Bajzik2, Zsuzsanna Lelovics3, Marianna Rakvács1, János Strausz1, Imre Repa3.   

Abstract

INTRODUCTION: Lung cancer has the highest mortality rate of all types of cancers both in developed countries and Hungary. AIM: To obtain experience and facilitate the application of low-dose computed tomography-based lung cancer screening as a targeted public health screening procedure.
METHOD: Volunteers without thoracic complaints above the age of 40 years (n = 963) were screened for lung cancer using digital chest radiography and low-dose computed tomography.
RESULTS: Two lung cancers were found among the participants screened with digital chest radiography (0.2%). After informed consent, 173 individuals with normal chest radiography findings (n = 943) took the opportunity to voluntarily participate in low-dose computed tomography screening for lung cancer. After 3 or 12 months, 65 individuals had follow up control examinations based on the size and characteristics of the detected lesions. Among them, one participant was found to have lung cancer using low-dose computed tomography.
CONCLUSIONS: These results indicate that low-dose computed tomography-based lung cancer screening as a public health screening procedure can enhance the success of screening with 50% (from 0.2% to 0.3%). The cost-benefit ratio can be raised if chest radiography is performed prior to the low-dose computed tomography examination.

Entities:  

Keywords:  LDCT; alacsony dózisú CT-alapú tüdőrákszűrés; lung cancer; lung screening; tüdőrák; tüdőszűrés

Mesh:

Year:  2014        PMID: 24583559     DOI: 10.1556/OH.2014.29845

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  1 in total

1.  Characterization of Individuals Taking Part in Low Dose Computed Tomography (LDCT) Screening Program.

Authors:  Mariann Moizs; Gábor Bajzik; Zsuzsanna Lelovics; János Strausz; Marianna Rakvács; Péter Zádori; Árpád Kovács; Imre Repa
Journal:  Pathol Oncol Res       Date:  2015-05-25       Impact factor: 3.201

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.